STAAR Surgical’s (STAA) Hold Rating Reaffirmed at Needham & Company LLC

STAAR Surgical (NASDAQ:STAA)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports.

A number of other research firms have also weighed in on STAA. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Canaccord Genuity Group reduced their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and a consensus target price of $42.83.

STAAR Surgical Stock Down 3.2 %

STAA opened at $23.12 on Tuesday. The business has a 50 day moving average price of $26.43 and a two-hundred day moving average price of $32.94. STAAR Surgical has a 52 week low of $22.40 and a 52 week high of $52.68. The company has a market cap of $1.14 billion, a PE ratio of 52.55 and a beta of 0.63.

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 23,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was bought at an average cost of $24.33 per share, for a total transaction of $559,590.00. Following the acquisition, the insider now owns 10,848,631 shares of the company’s stock, valued at approximately $263,947,192.23. The trade was a 0.21 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 1.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds and other institutional investors have recently made changes to their positions in STAA. Arcadia Investment Management Corp MI acquired a new stake in STAAR Surgical in the 3rd quarter worth about $37,000. Quarry LP purchased a new position in shares of STAAR Surgical during the 3rd quarter worth about $50,000. Canada Pension Plan Investment Board acquired a new stake in shares of STAAR Surgical in the second quarter worth approximately $129,000. Quest Partners LLC acquired a new position in STAAR Surgical during the third quarter worth approximately $128,000. Finally, Van ECK Associates Corp increased its position in STAAR Surgical by 12.7% during the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock worth $129,000 after purchasing an additional 393 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.